• Dimetridazole MIP Sensor: Findings and Limits

  2026-10-10

  The 2020 Analytica Chimica Acta study developed a poly-arginine molecularly imprinted polymer sensor for selective electrochemical detection of Dimetridazole, also known as 1,2-Dimethyl-5-nitroimidazole. Its reported 0.1 nM detection limit and application to egg, milk, and honey demonstrate strong analytical potential, while the study design remains focused on residue measurement rather than antimicrobial or therapeutic activity.

• Dextran Sulfate Sodium Salt in Colitis Research

  2026-10-09

  Dextran sulfate sodium salt, including DSS (MW 35000-45000), is widely used as a chemical injury model for studying intestinal inflammation and mucosal repair. This overview separates supplier descriptions from peer-reviewed evidence, examines how DSS can frame questions about epithelial barrier failure, and discusses a 2026 Cell Death & Disease study reporting a GPR35-KLF5 repair circuit linked to tryptophan metabolism. It also defines the model’s boundaries: chemical epithelial injury is not equivalent to human ulcerative colitis, and mechanistic findings require independent replication and quantitative validation.

• Romidepsin (FK228): HDAC Biology & HCC Evidence

  2026-10-09

  Romidepsin, also called FK228, is a class I HDAC inhibitor used to study epigenetic modulation, cell-cycle arrest, and apoptosis. Recent hepatocellular carcinoma research links HDAC2-dependent SmD2 regulation to alternative splicing and PARP-inhibitor sensitivity, but the combination evidence remains preclinical.

• CD36 Lipid Signaling and Immune Escape in AML

  2026-10-08

  Guo et al. show that CD36 supports acute myeloid leukemia immune escape through a non-canonical lipid-sensing pathway in which oxidized LDL and palmitate jointly activate innate immune signaling, rather than simply fueling lipid oxidation. The study also reports that high-fat conditions and decitabine can intensify this immunosuppressive program, while statin-mediated pathway targeting improved decitabine responses in the reported models.

• Cleavage-Resistant TREM2 and Macrophage Efferocytosis

  2026-10-08

  Dong et al. engineered a cleavage-resistant TREM2 receptor that preserves DAP12-linked signaling when inflammatory ADAM17 activity would otherwise impair macrophage efferocytosis. In mouse models of metabolic-dysfunction-associated steatohepatitis and atherosclerosis, phosphatidylserine-functionalized lipid nanoparticles delivered CRT mRNA in situ and reduced apoptotic-cell accumulation and inflammation, while leaving important translational questions unresolved.

• Central Opioid Control of Mechanical Hypersensitivity

  2026-10-07

  Yin et al. (2024) identify a lateral parabrachial-to-hypothalamic-to-spinal circuit that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study separates mechanical pain outcomes from better-established thermal effects and provides convergent circuit evidence for spinal gate-control disruption as a central mechanism.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-10-07

  Satir and colleagues examined whether partial BACE inhibition could reduce amyloid-beta secretion without impairing synaptic transmission. In cultured rat cortical neurons, reductions below 50% were not associated with detectable synaptic dysfunction, whereas stronger inhibition reduced both amyloid-beta secretion and synaptic transmission, supporting a cautious exposure-response interpretation rather than a simple all-or-none model.

• PLGA Nano-Adjuvant and Mucosal Immunity in Chicks

  2026-10-06

  A 2026 Poultry Science study evaluated PEI-LSP-RA-PLGA, a layered PLGA-based nano-adjuvant designed to combine sustained release, intestinal targeting, and immune regulation in chicks receiving an inactivated H9N2 vaccine. The reported increases in serum IgG and intestinal IgA, together with chemokine-receptor and immune-pathway findings, support the platform as a promising research model, although its protective value, safety, and broader applicability require further validation.

• Oltipraz: Nrf2, MASLD, and Evidence Boundaries

  2026-10-06

  Oltipraz is a dithiolethione described as an Nrf2-pathway activator and inducer of phase II detoxification enzymes. Its product-level rationale is relevant to chemoprevention research, but evidence from a 2026 Qushi Huoxue ointment mouse study should not be treated as direct evidence for Oltipraz in MASLD.

• CFTRinh-172: Reading CFTR Trafficking Data

  2026-10-05

  CFTRinh-172 is a selective CFTR inhibitor that can provide a functional counterpoint to plasma-membrane trafficking measurements. This article explains how to interpret channel activity, surface abundance, and cell-context effects without confusing pharmacological inhibition with restoration of CFTR biology.

• Oltipraz and Nrf2: MASLD Research Context

  2026-10-05

  Oltipraz is a supplier-described Nrf2 pathway activator and phase II enzyme inducer with a research history in chemoprevention. A 2026 mouse study of Qushi Huoxue ointment links Nrf2-associated signaling, autophagy, and ferroptosis suppression in MASLD, but its findings do not establish that Oltipraz itself treats MASLD or reproduce the effects of a complex botanical formula.

• CHIR-99021: From Wnt Control to 3D Translation

  2026-10-04

  CHIR-99021, also known as CT99021, is best understood not merely as a GSK-3 inhibitor but as a tool for testing how pathway state shapes cell identity within increasingly complex human models. This article connects its established signaling rationale with findings from a vascularized neuron–microglia co-culture study, while separating direct evidence from translational hypotheses.

• Anti-ROR1 Antibody: Evidence Boundaries

  2026-10-03

  Anti-ROR1 Antibody (Zilovertamab) offers a focused way to examine ROR1 target engagement, while a recent DON hepatotoxicity study illustrates how mechanistic evidence should be interpreted. This article distinguishes binding, pathway modulation, and disease-level inference without overstating cross-domain relevance.

• Pifithrin-α for p53 Mechanism Studies

  2026-10-02

  Pifithrin-α (PFTα) is a practical p53 inhibitor for separating p53-driven transcriptional effects from downstream ferroptotic injury, apoptosis, and radiation responses. This guide converts a developmental neurotoxicity study into executable HT-22 workflows, controls, optimization strategies, and interpretation safeguards.

• S-Adenosylhomocysteine in Neural Methylation Assays

  2026-10-01

  S-Adenosylhomocysteine (SAH) enables controlled methyltransferase inhibition and SAM/SAH ratio modulation in cell-based experiments. This guide translates radiation-induced neural differentiation findings into practical SAH workflows, controls, and troubleshooting strategies without confusing a proposed metabolic perturbation with a mechanism established by the reference study.

7384 records 1/493 page Next 12345 下5页 Last page